NTLA (Intellia Therapeutics) Growth Rank: 7 (As of Sep. 15, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NTLA Intellia Therapeutics Inc NTLA
69 GF Score
Price $11.38
GF Value $13.16
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Intellia Therapeutics Growth Rank?

Intellia Therapeutics NTLA -4.30% 69 Growth Rank is 7 as of Sep. 15, 2026, which is at its 10-year median of 7.00. GuruFocus rates NTLA with a GF Score™ of 69/100 and a GF Value™ of $13.16 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Intellia Therapeutics has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Intellia Therapeutics Growth Rank Related Terms

NTLA vs RXRX, SEPN, DMRA: Growth Rank Comparison

For the Biotechnology subindustry, Intellia Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intellia Therapeutics Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Growth Rank falls into.


NTLA
69GF Score
Intellia Therapeutics Inc NTLA
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Intellia Therapeutics (NTLA) has a Growth Rank of 7 as of Sep. 15, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Intellia Therapeutics and its competitors. This is near median its historical median of 7.00. Over the past decade, Intellia Therapeutics' Growth Rank has ranged from 2.00 to 9.00.
Is Intellia Therapeutics' Growth Rank too high?
Intellia Therapeutics' current Growth Rank of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. Overall, Intellia Therapeutics has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Growth Rank compare to RXRX and SEPN?
Intellia Therapeutics' Growth Rank of 7 can be compared against companies in the Biotechnology industry. Historically, Intellia Therapeutics' own Growth Rank has ranged from 2.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current Growth Rank is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.16, compared to a current price of $11.38 — trading 13.6% below its estimated fair value. The current Growth Rank is 7, which is near median its 10-year median of 7.00. Intellia Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Growth Rank is 7 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (NTLA) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $11.38 is trading 13.6% below its estimated GF Value™ of $13.16. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for NTLA:

  • Growth Rank: 7 (near median its 10-year median of 7.00)
  • GF Value™: $13.16 vs. price of $11.38 (13.6% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intellia Therapeutics Business Description

Other Exchanges 0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
69GF Score

Get the complete analysis for NTLA

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.38
Price
$13.16
GF Value